BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the dismissal of a qui tam action filed against the Company.
On April 23, 2026, the United States District Court for the Eastern District of New York issued an order dismissing the matter.
There is no monetary payment associated with the dismissal.
The dismissal order follows the request, by the qui tam plaintiff, for dismissal of the case and the Department of Justice’s (DOJ) concurrence in that request.
The matter was initially filed on February 12, 2021, and led to a DOJ investigation. On October 8, 2024, CareDx announced that the DOJ had concluded its investigation into CareDx without any finding of wrongdoing and declined to take further action. CareDx has denied allegations of wrongdoing throughout.
About CareDx
CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. The Company’s integrated solutions include non‑invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant. CareDx is the leading provider of genomics‑based information for transplant patients. For more information, please visit www.caredx.com.
Contacts
CareDx
Media Contacts
Natasha Moshirian Wagner
nwagner@caredx.com
Investor Relations
Caroline Corner
investor@caredx.com
